Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286.

MLA

Brown, Kirstin L., et al. “Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium Tuberculosis by the Novel Drug Candidate GSK2556286.” Antimicrobial Agents and Chemotherapy, vol. 67, no. 1, Jan. 2023, p. e0129422. EBSCOhost, https://doi.org/10.1128/aac.01294-22.

APA

Brown, K. L., Wilburn, K. M., Montague, C. R., Grigg, J. C., Sanz, O., Pérez-Herrán, E., Barros, D., Ballell, L., VanderVen, B. C., & Eltis, L. D. (2023). Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. Antimicrobial Agents and Chemotherapy, 67(1), e0129422. https://doi.org/10.1128/aac.01294-22

Chicago

Brown, Kirstin L, Kaley M Wilburn, Christine R Montague, Jason C Grigg, Olalla Sanz, Esther Pérez-Herrán, David Barros, Lluís Ballell, Brian C VanderVen, and Lindsay D Eltis. 2023. “Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium Tuberculosis by the Novel Drug Candidate GSK2556286.” Antimicrobial Agents and Chemotherapy 67 (1): e0129422. doi:10.1128/aac.01294-22.